Eva Marina Stafford, NP
Adult Health · Baton Rouge, LANPI 1982938866
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 939 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 12.8% — the pattern of someone who eats at a lot of different presentations. Among adult health clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 939 payments — averaging $15.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Lilly USA, LLC$1K
- Novo Nordisk$1K
- AstraZeneca$1K
- GSK$1K
- Boehringer Ingelheim$799
- plus $7K from 54 others
What the payments were for
- Food & beverage$14,500100%
- Education$330%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$14,533 in reported general payments places this provider in the 95th percentile of 203 adult health providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 390 | $411,496 |
| MounjaroTirzepatide | 321 | $382,969 |
| OzempicSemaglutide | 249 | $328,967 |
| Repatha SureclickEvolocumab | 117 | $88,257 |
| TrulicityDulaglutide | 64 | $87,670 |
| LinzessLinaclotide | 83 | $72,854 |
| EliquisApixaban | 77 | $70,431 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 91 | $69,656 |
| Tresiba Flextouch U-200Insulin Degludec | 62 | $56,737 |
| XareltoRivaroxaban | 69 | $54,635 |
| TradjentaLinagliptin | 64 | $54,300 |
| JanuviaSitagliptin Phosphate | 65 | $50,823 |
| MyrbetriqMirabegron | 83 | $47,791 |
| FarxigaDapagliflozin Propanediol | 61 | $45,293 |
| Tresiba Flextouch U-100Insulin Degludec | 58 | $34,522 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Glyxambi | $799 | $493,938477 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,374 | $470,639385 claims |
| Novo NordiskOzempic | $1,229 | $328,967249 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $1,017 | $82,690115 claims |
| AbbVieLinzess, Synthroid | $1,856 | $77,081179 claims |
| PfizerEliquis | $713 | $70,43177 claims |
| MerckJanuvia, Belsomra | $346 | $63,56488 claims |
| Johnson & JohnsonXarelto | $212 | $54,63569 claims |
| AstraZenecaFarxiga, Symbicort | $1,017 | $49,12272 claims |
| Astellas Pharma US IncMyrbetriq | $349 | $47,79183 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $198 | $9,73011 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $33 | $8,535951 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 203 adult health providers in Louisiana.
Other adult health in Baton Rouge
- Joan SmithBaton Rouge$121K
- Deborah SmithBaton Rouge$18K
- Tanisha SmithBaton Rouge$17K
- Dustin DenicolaBaton Rouge$14K
- Wendy GillBaton Rouge$13K
- Jennifer LeblancBaton Rouge$12K
- Carrie PerryBaton Rouge$6K
- Auldyn HirscheyBaton Rouge$6K
- Colette BlanchardBaton Rouge$6K
- Stephanie AkunneBaton Rouge$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.